Book Value per Share: ImmunoPrecise (IPA)

Graphic logo of ImmunoPrecise Antibodies (IPA)

ImmunoPrecise Antibodies (IPA) effectively integrates AI algorithms with biotech for the rapid selection of therapeutic antibodies, eliminating price wars with conventional laboratories. The target book value per share demonstrates asset resilience, with the current level sitting around 0.37. The business's sustainability is supported by virtual testing that reduces chemical waste, while database cybersecurity ensures ethical management.

ImmunoPrecise (IPA) Equity per Share: for the period 07/04/2022 - 09/04/2025

ImmunoPrecise Antibodies Ltd - analytical breakdowns and key metrics (IPA)

- price and consensus price forecast:
Stock Price ImmunoPrecise|IPA - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization ImmunoPrecise Antibodies Ltd.|IPA - Business Value
- book capitalization data:
Net Assets per Single Share ImmunoPrecise Antibodies|IPA - Accounting Capitalization|Market Capitalization to Book Value Ratio immunoprecise.com|IPA - Company Total Assets
- debt and liquidity data:
Total Debt to Capital ImmunoPrecise Antibodies|IPA - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity ImmunoPrecise|IPA - Company Total Debt|Debt to Book Capitalization Ratio ImmunoPrecise Antibodies Ltd.
Fundamental company valuation:immunoprecise.com - IPA
Product sample of ImmunoPrecise

For ImmunoPrecise Antibodies (IPA), which is scaling AI-driven antibody development via the BioStrand platform, the book value per share trend reflects the efficiency of capitalizing intellectual assets and libraries. This indicator is calculated as the difference between total assets and liabilities divided by the number of shares outstanding, allowing investors to track the real value of the company's assets and identify hidden equity dilution.

Competitor analysis

Tempus AI, Inc. - Book Value per Share|QGEN - Book Value per Share|Book Value per Share Ionis Pharmaceuticals|RGEN (repligen.com) - Equity per Share|Net Assets per Single Share Avidity Biosciences, Inc. (RNA)|Equity per Share CRISPR Therapeutics Inc|Book Value per Share WGS|Book Value per Share Ultragenyx Corp (RARE)|Book Value per Share BEAM|sarepta.com - Net Assets per Share|TWST: Net Assets per Single Share|TXG: Accounting Value per Share|NTLA (Intellia) - Net Assets per Single Share|Accounting Value per Share Stoke Corp|BLFS (BioLife Solutions, Inc.) - Accounting Value per Share|Book Value per Share WVE|Net Assets per Single Share Maze Therapeutics MAZE|Equity per Share SION (Sionna Therapeutics, Inc.)|PRME: Net Assets per Single Share|Taysha Corp - Net Asset Value per Share|Net Assets per Single Share uniQure N.V.|MGTX: Share Book Value|Net Assets per Single Share REGENXBIO RGNX|Solid Biosciences Inc (SLDB) - Accounting Value of a Share|Book Value per Share OCGN (Ocugen Corp)|Net Asset Value per Share PacBio Corp|Book Value per Share BNTC (Benitec Biopharma Inc.)|Accounting Value per Share designtx.com (DSGN)|Book Value per Share RCKT|4DMT - Net Assets per Share|Net Assets per Single Share LXEO (Lexeo)|KRRO - Net Assets per Share|Book Value per Share EDIT|Net Asset Value per Share silence-therapeutics.com|PRQR - Accounting Value per Share|Accounting Value of a Share Codexis Bio|Book Value per Share SGMO|Book Value per Share NAUT (nautilus.bio)|MGX - Net Assets per Single Share|DTIL - Equity per Share|Accounting Value per Share Generation Bio Corp GBIO|BOLD - Book Price of a Share|exicuretx.com - Book Value per Share|Imunon (IMNN) - Net Assets per Share|Book Value per Share Phio Pharmaceuticals Corp|Net Assets per Single Share MBIO|TransCode Therapeutics - Net Assets per Single Share|Net Asset Value per Share bionanogenomics.com (BNGO)|APDN - Book Value per Share|Equity per Share bluebird bio, Inc BLUE|Book Value per Share OMGA (Omega Therapeutics)|OMIC - Net Assets per Share|Book Value per Share RGLS|SYRS (Syros Pharmaceuticals Inc.) - Net Asset Value per Share|TBIO: Net Assets per Single Share|Net Assets per Share TRACON Pharmaceuticals, Inc|UBX (Unity Biotechnology) - Book Value per Share